CURIS INC (CRIS)
D
Pipeline Grade
Financial Position (from SEC Filings)
$15.5M
Cash & Equivalents
$9.0M
Quarterly Burn Rate
5 mo
Est. Cash Runway
$10M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (4)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07271667 | A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Le... | PHASE2 | Recruiting | 108 |
| NCT07107750 | Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or ... | PHASE1 | Recruiting | 48 |
| NCT03893487 | Fimepinostat in Treating Brain Tumors in Children and Young Adults | PHASE1 | Active Not Recruiting | 30 |
| NCT05187182 | CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Canc... | PHASE1 | Recruiting | 42 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.